- Previous Close
8.40 - Open
8.45 - Bid 8.45 x 25800
- Ask 9.50 x 24800
- Day's Range
8.45 - 8.45 - 52 Week Range
4.76 - 8.95 - Volume
100 - Avg. Volume
42 - Market Cap (intraday)
357.697M - Beta (5Y Monthly) 0.67
- PE Ratio (TTM)
-- - EPS (TTM)
-5.80 - Earnings Date Jan 8, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
AngioDynamics, Inc., a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit, indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. The company also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. In addition, it provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. The company was founded in 1988 and is headquartered in Latham, New York.
www.angiodynamics.comRecent News: UG2.F
View MorePerformance Overview: UG2.F
Trailing total returns as of 12/31/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: UG2.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: UG2.F
View MoreValuation Measures
Market Cap
352.63M
Enterprise Value
304.49M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.22
Price/Book (mrq)
1.82
Enterprise Value/Revenue
1.08
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-83.02%
Return on Assets (ttm)
-6.12%
Return on Equity (ttm)
-77.85%
Revenue (ttm)
292.73M
Net Income Avi to Common (ttm)
-243.03M
Diluted EPS (ttm)
-5.80
Balance Sheet and Cash Flow
Total Cash (mrq)
55.01M
Total Debt/Equity (mrq)
2.76%
Levered Free Cash Flow (ttm)
24.19M